Calithera Biosciences Stock Price, Forecast & Analysis (NASDAQ:CALA)

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences Inc (NASDAQ:CALA) posted its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.18. View Calithera Biosciences' Earnings History.

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Calithera Biosciences.

2 brokerages have issued twelve-month price objectives for Calithera Biosciences' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Calithera Biosciences' stock price to reach $8.00 in the next year. This suggests a possible upside of 146.2% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.

Media stories about CALA stock have trended very negative on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Calithera Biosciences earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Calithera Biosciences.

Calithera Biosciences saw a increase in short interest in October. As of October 31st, there was short interest totalling 1,810,000 shares, an increase of 21.5% from the September 30th total of 1,490,000 shares. Based on an average daily volume of 323,400 shares, the days-to-cover ratio is currently 5.6 days. Approximately 5.2% of the shares of the stock are sold short. View Calithera Biosciences' Current Options Chain.

Some companies that are related to Calithera Biosciences include Kura Oncology (KURA), Revance Therapeutics (RVNC), ANI Pharmaceuticals (ANIP), IGM Biosciences (IGMS), Organogenesis (ORGO), Omeros (OMER), Collegium Pharmaceutical (COLL), Flexion Therapeutics (FLXN), Emisphere Technologies (EMIS), Akorn (AKRX), OrganiGram (OGI), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), DiaMedica Therapeutics (DMCAF) and ChemoCentryx (CCXI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and Synergy Pharmaceuticals (SGYP).

Calithera Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rhumbline Advisers (0.11%), Grimes & Company Inc. (0.04%), Wedbush Securities Inc. (0.03%) and Assenagon Asset Management S.A. (0.02%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Susan Molineaux and Value Fund L P Biotechnology. View Institutional Ownership Trends for Calithera Biosciences.

CALA stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Calithera Biosciences.

CALA stock was bought by a variety of institutional investors in the last quarter, including Grimes & Company Inc., Wedbush Securities Inc. and Rhumbline Advisers. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, Susan Molineaux and Value Fund L P Biotechnology. View Insider Buying and Selling for Calithera Biosciences.

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CALA stock can currently be purchased for approximately $3.25.

Calithera Biosciences has a market capitalization of $174.75 million and generates $22.25 million in revenue each year. The biotechnology company earns $-54,630,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe.View Additional Information About Calithera Biosciences.

The official website for Calithera Biosciences is http://www.calithera.com/.

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]